Europe watchdog advises suspending 'risky' osteoporosis drug

A committee of Europe's medicines watchdog on Friday recommended suspending the use of an osteoporosis drug, saying the risks, including heart attacks, outweighed the benefits.

The drug, Protelos/Osseor, is prescribed for people with the bone-crumbling disease who often suffer debilitating fractures.

A product of French firm Servier Laboratories, the medicine is said to make bones stronger and prevent breaks.

But the PRAC risk assessment committee of the European Medicines Agency (EMA) said the risks of serious , including heart attacks, blood clots and blocked arteries, were just too great.

For every 1,000 treated patients, there were four additional cases of serious heart problems and four of clotting among people using Protelos/Osseor compared to those given a placebo or dummy treatment.

Other risks include seizures and liver inflammation.

As an osteoporosis treatment, the drug has shown a "modest effect"—preventing about five non-spinal bone fractures, 15 and 0.4 hip fractures per 1,000 patients, the committee said.

"The PRAC weighed the benefits of the medicine against the known risks and concluded that the balance was no longer favourable, and recommended Protelos/Osseor be suspended until there are new data showing a favourable balance in a defined patient group," a statement said.

The recommendation will next be considered by the EMA's Committee for Medicinal Products for Human Use for a final decision.

Servier in a statement informed national health agencies of Friday's announcement, and said it would provide further information once the EMA review is concluded.

add to favorites email to friend print save as pdf

Related Stories

Alendronate reduces adjacent-level vertebral fractures

Dec 30, 2013

(HealthDay)—For females with osteoporosis, the rate of adjacent-level vertebral fractures is relatively low, with reduced odds with bisphosphonate therapy, according to a study published in the Dec. 1 issue ...

Recommended for you

Added benefit of vedolizumab is not proven

7 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments